Payment overview · 2025
General Payments
$105.53
6 reported records · 5 companies
Healthcare provider profile · identity verified
Hannah Haack, MD
Allopathic & Osteopathic Physicians|Family Medicine · SMITH CENTER, KS · NPI 1649567397
Verified facts
What the public records show
CMS Open Payments records show Hannah Haack, MD received $105.53 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 40.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.39 | 40.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.33 | 17.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.31 | 15.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.90 | 14.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.60 | 12.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $105.53 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 508 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 306 | 55 |
| Losartan Potassium | Losartan Potassium | 287 | 43 |
| Furosemide | Furosemide | 280 | 50 |
| Gabapentin | Gabapentin | 237 | 48 |
| Omeprazole | Omeprazole | 237 | 52 |
| Potassium Chloride | Potassium Chloride | 230 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 29 |
| Tramadol Hcl | Tramadol Hcl | 192 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 40 |
| Lisinopril | Lisinopril | 155 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 24 |
| Metformin Hcl | Metformin Hcl | 146 | 19 |
| Sertraline Hcl | Sertraline Hcl | 138 | 20 |
| Eliquis | Apixaban | 131 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 13 |
| Metformin Hcl Er | Metformin Hcl | 114 | 22 |
| Montelukast Sodium | Montelukast Sodium | 110 | 14 |
| Trazodone Hcl | Trazodone Hcl | 107 | 20 |
| Carvedilol | Carvedilol | 105 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 17 |
| Spironolactone | Spironolactone | 86 | 18 |
| Warfarin Sodium | Warfarin Sodium | 85 | 11 |
| Simvastatin | Simvastatin | 83 | 14 |
| Famotidine | Famotidine | 82 | 16 |
| Myrbetriq | Mirabegron | 78 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 74 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 11 |
| Pregabalin | Pregabalin | 69 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 12 |
| Allopurinol | Allopurinol | 64 | suppressed |
| Alprazolam | Alprazolam | 63 | 11 |
| Colestipol Hcl | Colestipol Hcl | 63 | 13 |
| Prednisone | Prednisone | 61 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 17 |
| Meloxicam | Meloxicam | 58 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | suppressed |
| Lorazepam | Lorazepam | 55 | 12 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 54 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | suppressed |
| Mirtazapine | Mirtazapine | 53 | suppressed |
| Baclofen | Baclofen | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Jardiance | Empagliflozin | 49 | suppressed |
| Sucralfate | Sucralfate | 49 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Rybelsus | Semaglutide | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 16 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nystatin | Nystatin | 20 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Captopril | Captopril | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $105.53 · 6 records | ABBVIE INC. | EVENITY, JARDIANCE, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error